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O B J E C T I V E S This study sought to investigate the association between thrombin generation in
plasma and the presence and severity of computed tomography angiographically deﬁned coronary
atherosclerosis in patients with suspected coronary artery disease (CAD).
B A C KG ROUND Besides its pivotal role in thrombus formation, experimental data indicate that
thrombin can induce an array of pro-atherogenic and plaque-destabilizing effects. Although thrombin
plays a role in the pathophysiology of atherosclerosis progression and vascular calciﬁcation, the clinical
evidence remains limited.
METHOD S Using 64-slice coronary computed tomographic angiography, we assessed the presence
and characteristics of CAD in patients (n  295; median age 58 years) with stable chest pain. Coronary
artery calciﬁcation was graded as absent (Agatston score 0), mild (Agatston score 1 to 100), moderate
(Agatston score 101 to 400), and severe (Agatston score 400). Calibrated automated thrombography
was used to assess endogenous thrombin potential in plasma in vitro. Thrombin-antithrombin complex
(TATc) levels were measured as a marker for thrombin formation in vivo.
R E S U L T S TATc plasma levels were substantially higher in patients with CAD versus patients without
CAD (p 0.004). Signiﬁcant positive correlations were observed between steadily increasing TATc levels
and the severity of CAD (r  0.225, p  0.001). In multinomial logistic regression models, after adjusting
for established risk factors, TATc levels predicted the degree of coronary artery calciﬁcation: mild (odds
ratio: 1.56, p  0.006), moderate (odds ratio: 1.56, p  0.007), and severe (odds ratio: 1.67, p  0.002).
Trends were comparable between the groups when stratiﬁed according to the degree of coronary
luminal stenosis.
CONC L U S I O N S This study provides novel clinical evidence indicating a positive independent
association between enhanced in vivo thrombin generation and the presence and severity of coronary
atherosclerosis, which may suggest that thrombin plays a role in the pathophysiology of vascular
calciﬁcation and atherosclerosis progression. (J Am Coll Cardiol Img 2012;5:1201–10) © 2012 by the
American College of Cardiology Foundation
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1202therosclerosis is a multifactorial chronic in-
flammatory vascular disorder (1,2). Given
the abundant experimental evidence show-
ing extensive interactions between the
hemostatic, immune, and inflammation systems, we
have proposed a role for the clotting proteins in
modulating atherosclerosis progression and athero-
sclerotic plaque phenotype (3). In particular,
thrombin, which is the most central coagulation
protein, is also recognized as a strong pro-
inflammatory mediator. Endowed with a potent cell
signaling capacity, thrombin can induce an array of
pro-atherogenic and plaque-destabilizing effects
such as inflammation, vascular smooth muscle cell
migration and proliferation, leukocyte chemotaxis,
proteolysis, apoptosis, and angiogenesis (3,4). Re-
cently, we demonstrated that thrombin, as
well as other coagulation proteins, are
widely expressed and functionally active
throughout distinct compartments of the ar-
terial vessel wall (5), supporting an active
cell-based coagulation network within hu-
man atherosclerotic plaques. G-protein–
coupled protease-activated receptors,
which are selectively cleaved by thrombin,
are also abundantly distributed in the vas-
culature under normal conditions and
overexpressed in atherosclerotic lesions
(6). Experimental animal studies have
clearly indicated that variations in the
clotting activity affect the progression
and thrombogenicity of atherosclerotic
plaques (3).
Antithrombotic therapy is a cornerstone
in the management and prevention of
atherothrombosis in patients (2). Experi-
mental data demonstrate that direct
thrombin inhibition substantially attenu-
ates atherosclerosis development in ApoE-null
mice (7) and protects against severe plaque progres-
sion in prothrombotic mice (8). However, the role
of blood coagulation proteins in atherogenesis, in
particular thrombin, has not been adequately ad-
dressed in previously conducted clinical research.
Cardiac computed tomographic angiography
(CCTA) is a well-established noninvasive imaging
modality, which has high diagnostic accuracy for
detection and characterization of coronary athero-
sclerotic plaques (9,10). Using CCTA, we investi-
gated the association between thrombin formation
in plasma and the presence and severity of coronary
atherosclerosis in patients with suspected coronary
istic
se
y
n
re
binartery disease (CAD). aM E T H O D S
Study population. We studied 295 adult patients who
ere referred from the cardiology outpatient depart-
ent for CCTA because of stable chest pain, sus-
ected for CAD. Scans were performed in our uni-
ersity medical center between January 2008 and June
010 as part of the diagnostic work-up in these
atients. Included were patients with a recent history
f (a)typical chest pain, who underwent a coronary
alcium score scan as well as CCTA. Excluded were
atients with acute chest pain suspected for an acute
oronary syndrome; patients with a history of acute
yocardial infarction, percutaneous coronary inter-
ention, and/or coronary artery bypass grafting sur-
ery; patients with missing data regarding their cardiac
isk profile; patients with an inconclusive computed
omography (CT) scan; and patients currently on
nticoagulation therapy (oral vitamin K antagonist/
elective anticoagulants or low-molecular-weight
eparins). In vitro hemolysis of blood samples was also
n exclusion criterion. We calculated the Framingham
isk Score (FRS) in all patients to estimate the
0-year risk of having a myocardial infarction or
ardiovascular death (11). The Institutional Review
oard and Ethics Committee at the Maastricht Uni-
ersity Medical Center approved the study, and all
atients gave written informed consent.
CCTA protocol. Scans were performed using a 64-slice
ultidetector-row CT scanner (Brilliance 64; Philips
ealthcare, Best, the Netherlands) with a 64 
.625-mm slice collimation, a gantry rotation time of
20 ms, and a tube voltage of 80 to 120 kV. Tube
urrent varied from 150 to 210 mAs for the prospec-
ively gated “step and shoot” protocol and from 600 to
,000 mAs for the retrospectively gated “helical”
rotocol, depending on patients’ weight and height.
atients received 50 mg metoprolol tartrate orally, 2 h
efore CCTA. When indicated, an additional dose of
to 20 mg metoprolol tartrate (AstraZeneca, Zoeter-
eer, the Netherlands) was administered intrave-
ously to lower the heart rate to 65 beats/min. A
ose of 0.8 mg nitroglycerin spray (Pohl-Boskamp,
ohenlockstedt, Germany) was given sublingually
ust prior to CCTA. Heart rate and electrocardiogram
ere monitored during CCTA.
A nonenhanced scan was performed to determine
he amount of coronary artery calcification (CAC),
sing the Agatston method (12). Subsequently,
CTA was performed using 85 to 110 ml of contrast
gent (Xenetix 350, Guerbet, Roissy CdG Cedex,
rance), which was injected in the antecubital vein atA B B R E V I A T I O N S
A N D A C R O N YM S
AUROC area under the
receiver-operating character
curve
CAC coronary artery
calcification
CAD coronary artery disea
CAT calibrated automated
thrombography
CCTA cardiac computed
tomographic angiography
CI confidence interval
CT computed tomograph
ETP endogenous thrombi
potential
FRS Framingham Risk Sco
OR odds ratio
TATc thrombin-antithromrate of 6.0 ml/s, directly followed by 40 ml intrave-
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1203nous saline (6.0 ml/s) using a dual-head power injec-
tor. A prospectively gated “step and shoot” protocol
was used in all patients with a stable heart rate 65
beats/min. In patients with an irregular heart rate or a
stable heart rate 65 beats/min, we used a retrospec-
ively gated “helical” protocol with dose modulation to
btain the best image quality at minimal radiation
ose (13,14).
CCTA analysis. All scans were independently ana-
yzed by 2 cardiologists with level III expertise in
oronary CT angiography, blinded for patient de-
ails, using source images in the Cardiac Compre-
ensive Analysis software (Philips Healthcare). In
ase of disagreement, consensus was reached by
eviewing findings jointly.
CAC was expressed as the Agatston score using
alcium scoring software (Philips Healthcare) with a
hreshold of 130 Hounsfield units (HU). The coro-
ary artery tree was analyzed for the presence and
everity of CAD, according to the 16-segment classi-
cation of the American Heart Association (15).
oronary plaques were defined as visible structures
ithin or adjacent to the coronary artery lumen, which
ould be clearly distinguished from the vessel lumen
nd the surrounding pericardial tissue. Plaques were
ategorized as calcified (exclusively content with den-
ity130 HU), noncalcified (exclusively content with
ensity 130 HU), or mixed (characteristics of both
alcified and noncalcified plaques). The degree of
AD was classified as absent (no luminal stenosis),
ild (50% luminal stenosis), moderate (50% to 70%
uminal stenosis), or severe (70% luminal stenosis)
16). The degree of CAC was classified as absent
Agatston score 0), mild (Agatston score 1 to 100),
oderate (Agatston score 100 to 400), or severe
Agatston score 400) (17).
Blood samples and laboratory measurements. Blood
samples were taken just before the scan and pro-
cessed within 2 h, and plasma was stored at 80°C
until analysis. Continuous thrombin generation in
clotting platelet-poor plasma was monitored in
vitro by using the Calibrated Automated Throm-
bography (CAT) method (Thrombinoscope B.V.,
Maastricht, the Netherlands) (18). The reaction
was triggered by adding 5pM tissue factor (PPP
Reagent, Thrombinoscope B.V.) in the presence of
4 M phospholipids and 16 mM added CalCl2 (in
duplicate). Endogenous thrombin potential (ETP)
was analyzed (corresponds to the area under the
curve). ETP values were normalized on the basis of
platelet-poor normal pooled plasma obtained from
healthy volunteers, the latter used as a reference
(19). Data are expressed as percent of normal 2pooled plasma (20). In addition, using a commer-
cially available microenzyme immunoassay kit
(Enzygnost TAT Micro, Siemens Healthcare Di-
agnostics, Deerfield, Illinois) we established
thrombin-antithrombin complex (TATc) levels in
all patients (in duplicate) as a highly specific marker
for thrombin formation in vivo.
Statistical analysis. Statistical analyses were per-
formed using IBM SPSS Statistics 19.0.0 (SPSS
Inc., Chicago, Illinois). Categorical variables are
presented as numbers (percentages), whereas con-
tinuous data are expressed as mean  SD, unless
otherwise indicated. TATc plasma levels were nor-
malized by natural logarithm transformation. We
used the score plus 1 to also include patients with a
TATc plasma level below 1 ng/ml. Demographic
differences between patients with or without CAD
were tested using either Student’s t test or Mann-
hitney U test, depending on the distribution
haracteristics of the data. Pearson’s chi-square test
as used to compare proportions (binary or cate-
orical), whereas continuous variables were ana-
yzed via 1-way analysis of variance test, including
onferroni correction. Correlations are presented as
earson or Spearman coefficients according to the
bserved distribution. Multivariate analyses were
onducted using binary/multinomial logistic regres-
ion, computed in a multiple main effects or forward
tepwise manner, including variables with p 0.05.
earson’s chi-square test and odds ratios (ORs)
ith 95% confidence intervals (CIs) were calculated
o determine which variables demonstrated signifi-
ant independent associations with atherosclerotic
laque presence, degree of luminal stenosis, and
AC. Receiver-operating characteristic analysis
as carried out to evaluate the potential of using
ATc and FRS (separately or in combination) for
etermining the presence or absence of CAD.
reas under the receiver-operating characteristic
urve (AUROC) were compared using the Hanley
nd McNeil’s method. We performed the net re-
lassification index to evaluate the incremental ef-
ect of adding TATc to the FRS for predicting the
resence of coronary plaques. A 2-sided p value
0.05 was considered statistically significant.
R E S U L T S
Study population characteristics. The study popula-
ion consisted of 295 individuals (182 men [61.7%]
nd 113 women [38.3%]) with a median age of 57
ears (minimum to maximum: 30 to 87). A total of
26 patients underwent a “step and shoot” scan
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1204(mean radiation dose 3.6 mSv), whereas 69 patients
underwent a “helical” scan (mean radiation dose
11.6 mSv). CAD was detected in 205 (69.5%)
patients. The prevalence of absent, mild, moderate,
and severe CAD was 30.5%, 22.7%, 26.4%, and
20.3%, respectively. Compared to the non-CAD
group, patients with CAD were predominantly
male (65.4%) and older, showed increased systolic
blood pressure, and had lower low-density lipopro-
tein plasma concentrations. However, the preva-
lence of statin use in the CAD group was signifi-
cantly higher compared with the non-CAD group
(100 [48.8%] vs. 22 [24.4%]). Baseline characteris-
tics are presented in Table 1.
Increased in vivo thrombin formation independently
reﬂects the presence of coronary atherosclerotic
plaques. As depicted in Figure 1A, among the
population with CAD (n  205), the average
aseline (lg 10 transformed) TATc levels were
ignificantly higher compared with the group with-
ut CAD (mean 0.41 [95% CI: 0.38 to 0.45] vs.
ean 0.32 [95% CI: 0.29 to 0.36]; p  0.001).
Multivariate logistic regression analysis showed that
higher TATc levels (OR: 1.47, 95% CI: 1.10 to
1.97, p  0.010), in addition to other established
risk factors such as male gender (OR: 3.36, 95% CI:
1.75 to 6.45, p  0.001), age (OR: 1.09, 95% CI:
1.05 to 1.12, p  0.001), and smoking (OR: 2.17,
Table 1. Baseline Characteristics of Subjects Stratiﬁed Into Grou
All Participants
(n  295)
P
Age, yrs 57 (30–87)
Male 182 (61.7)
BMI, kg/m2 26.4 (24.2–29.4)
Systolic blood pressure, mm Hg 143 (130–156)
Diastolic blood pressure, mm Hg 80 (73–87)
Smoking 71 (24.1)
Diabetes mellitus 26 (8.8)
Positive family history 126 (42.7)
Lipid-lowering therapy 122 (41.4)
Anticoagulation therapy 0 (0)
Framingham Risk Score 18.9 (12.3–30.0)
Total cholesterol, mg/dl 213 (174–244)
LDL, mg/dl 128 (101–166)
HDL, mg/dl 46 (35–58)
Triglycerides, mg/dl 134 (90–208)
Coronary atherosclerotic lesions 2 (0–5)
CAC (Agatston score) 27 (0–214)
Values are median (interquartile range), or n (%). *Patients with no angiographi
detected coronary atherosclerotic plaque(s). Statistical signiﬁcance at the p 
BMI  body mass index; CAC  coronary artery calciﬁcation; CAD  coronar
HDL  high-density lipoprotein.5% CI: 1.09 to 4.33, p  0.001), were all inde- cendently associated with the presence of CAD
data not shown). AUROC for coronary plaque
resence, calculated by using the FRS, was 0.663
95% CI: 0.61 to 0.72, p  0.001). Addition of
ATc as a marker to the FRS improved the
redictive value, resulting in a significant increase of
he AUROC to 0.676 (95% CI: 0.62 to 0.73, p 
.048 – difference between areas). The net reclas-
ification index to assess the incremental value of
ATc over the FRS in predicting the presence of
oronary plaques was 3.1%, which was not signifi-
ant (p  0.68).
CAT measurement, which was carried out to assess
he potential to generate thrombin in vitro, resulted in
TP values, which were almost the same in the
on-CAD group and the CAD group (Fig. 1B).
TATc as determinant of CAC and luminal stenosis. In
the entire study population, TATc levels showed a
significant positive association with the degree of
CAC (Agatston score, r  0.209, p  0.001), as
resented in Figure 2A. In contrast, no significant
elationship was noted between TATc concentra-
ions and the number of noncalcified plaques (r 
.052, p  0.376). Multivariate logistic regression
nalyses, using multiple main effects and forward
tepwise techniques, identified higher TATc for-
ation as an independent risk factor for developing
AC (Table 2). Compared to a reference group,
per Presence of CT-Angiographic CAD
ents Without CAD*
(n  90)
Patients With CAD†
(n  205) p Value
54 (30–76) 59 (36–87) 0.001
48 (53.3) 134 (65.4) 0.053
26.6 (23.8–29.7) 26.4 (24.3–29.3) 0.620
139 (127–153) 145 (132–157) 0.023
80 (71–86) 81 (74–87) 0.615
18 (20.0) 53 (25.9) 0.304
6 (6.7) 20 (9.8) 0.505
36 (40.0) 90 (43.9) 0.609
22 (24.4) 100 (48.8) 0.005
0 (0) 0 (0) —
14.1 (9.8–21.4) 21.6 (13.4–33.1) 0.001
217 (192–240) 205 (170–247) 0.077
135 (116–163) 124 (97–166) 0.043
46 (35–57) 44 (37–58) 0.980
146 (91–231) 130 (89–202) 0.180
0 (0–0) 4 (2–7) 0.001
0 (0–0) 117 (23–355) 0.001
detected coronary atherosclerotic plaques. †Patients with 1 angiographically
level.
ery disease; CT  computed tomography; LDL  low-density lipoprotein;ps
ati
cally
0.05
y artonsisting of all patients without any coronary
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1205calcifications, the ORs associated with CAC bur-
den were as follows: mild CAC (OR: 1.60, 95% CI:
1.18 to 2.16, p  0.005); moderate CAC (OR:
1.58, 95% CI: 1.16 to 2.15, p  0.005); and severe
CAC (OR: 1.71, 95% CI: 1.26 to 2.33, p 0.005).
As shown in Figure 2B, we also found a significant
difference in the distribution of the TATc quartiles
(Q1 to Q4) between the different CAC groups (p
0.002). While in the no CAC group, 35.9% of the
patients had TATc values in the lowest quartile
(Q1) and only 14.6% of them had values in the
highest quartile (Q4), the distribution of the TATc
quartiles in the severe CAC group was 9.3% and
41.9% in Q1 and Q4, respectively.
There was a strong positive association between
Agatston score and severity of CAD (r  0.712,
 0.001). Nevertheless, we also tested the rela-
ionship between TATc formation and the degree
f luminal stenosis by performing multivariate lo-
istic regression analyses with degree of luminal
tenosis as a dependent variable. Similarly, TATc
oncentrations accurately identified worsening ath-
rosclerosis. The ORs associated with mild, mod-
rate, and severe CAD are depicted in Table 3.
Furthermore, we found a U-shaped relationship
etween the potential to generate thrombin in vitro
nd the extent of CAD (Fig. 3). Within the group of
atients with detected CAD, ETP did not correlate to
he extent of CAC (r0.036, p 0.604), whereas
t was significantly associated with the degree of CAD
r  0.271, p  0.001). In a multivariate logistic
egression analysis, when compared with mild CAD,
he ORs associated with moderate and severe CAD
ere as follows: moderate (OR: 1.02, 95% CI: 1.00 to
.04, p 0.056) and severe (OR: 1.04, 95% CI: 1.02
o 1.06, p  0.001).
D I S C U S S I O N
Major ﬁndings. The present study examines the
elationship between thrombin formation and
AD. In a cohort of 295 patients with suspected
AD, we established baseline TATc concentra-
ions in plasma and used CCTA imaging to assess
he presence and severity of coronary atherosclerotic
laques. We found several novel findings of poten-
ial clinical relevance. The primary observation of
his study is that higher TATc levels, the latter
onsidered a sensitive marker of thrombin forma-
ion in vivo, are independently related to the pres-
nce and severity of CAD. Net reclassification
ndex analysis showed that incorporation of TATc
s an additional test did not significantly improves the cardiovascular risk stratification capacity of the
RS. On the other hand, the amount of CAC and
egree of luminal stenosis were consistently higher
ith increasing thrombin generation, indicating
hat TATc measurement is useful to detect even
ild-grade CAC or stenosis. In daily practice,
ATc concentrations may therefore contribute to
redict which patients are more likely to have
AD. However, as a single biomarker it seems not
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1206diagnostic imaging tools like CCTA, magnetic
resonance imaging, ultrasound, nuclear imaging
tests, or invasive coronary angiography.
The detrimental role of thrombin in athero-
thrombosis is not a matter of dispute (21). Numer-
ous previously published reports have documented
increased rates of thrombin synthesis and blood
coagulation activation upon the onset of major
adverse cardiovascular events (22–25). However,
besides being linked to blood thrombogenicity and
determining the magnitude of thrombus formation
upon atherosclerotic plaque rupture, thrombin ac-
tivity per se may be also relevant to the pathophys-
Agatston Group
Coronary Artery Calcification (CAC)
*
n =103
No
0
0.32
(0.29 - 0.35)
*
n = 83
Mild
1-100
0.41
(0.36 - 0.46)
*
n = 66
Moderate
101-400
0.39
(0.33 - 0.44)
n = 43
Severe
> 400
0.50
(0.41 - 0.59)
Agatston Group
Coronary Artery Calcification (CAC)
No Mild Moderate Severe
Q4
Q3
Q2
Q1
35.9
25.2
24.3
14.6
18.1
31.3
19.3
31.3
25.8
19.7
31.8
22.7
9.3
20.9
27.9
41.9
Independent Predictor of CAC
n gradually increasing thrombin-antithrombin complex (TATc)
erity of coronary artery calciﬁcation (CAC). Bars represent lg 10
ls, presented as mean (95% conﬁdence interval), stratiﬁed per
signiﬁcance at the p  0.05 level when compared with the
Distribution of TATc quartiles between CAC score groups.iology of atherosclerosis progression (3,4). Several firesearch groups have attempted to study the rela-
tionship between hypercoagulability and atheroscle-
rosis progression by assessing ankle brachial pres-
sure index in patients with peripheral artery disease
(26–28) or evaluating other markers of subclinical
atherosclerosis such as carotid intima-media thick-
ness (29,30). Nevertheless, these studies do not
provide sufficient insight into this problem due to
the very limited potential of ankle brachial pressure
index and carotid intima-media thickness tech-
niques to evaluate CAD. To our knowledge, this is
the first study to precisely examine the relationship
between thrombin generation and the angiographic
presence, severity, and calcification of coronary
artery plaques by using CCTA in a population with
suspected, but not previously established CAD.
Enhanced in vivo thrombin generation during athero-
genesis: potential clinical implications. Given the ca-
pacity of thrombin to modulate pro-atherogenic
actions related to plaque destabilization, it becomes
important to define what the clinical implications of
these findings may be. Previously, we have demon-
strated that early atherosclerotic lesions exert an
enhanced pro-coagulant state in comparison to
stable advanced ones (5). This phenomenon was
partially explained by the increased activity of many
key coagulation proteins (including thrombin), but
also by the ability of different vascular cell types to
synthesize coagulation factors at a local level. There
is abundant histopathological and experimental ev-
idence to demonstrate that thrombosis occurs long
before an atherosclerotic plaque ruptures, named as
subclinical or “buried” thrombosis (8,31,32). The
latter is also considered a potential trigger of plaque
vulnerability (33–35). Furthermore, blood coagulation
is an important component of the host-defense system
to fight tissue injury and infection (36). Despite that
the exact mechanisms of the enhanced TATc forma-
tion in blood during atherosclerosis progression re-
main unclear to date, one may speculate that inflam-
mation and coagulation operate in a perpetual mode
to repair worsening atherosclerosis vascular damage.
While oral vitamin K antagonists and antiplatelet
therapy remain the cornerstone in primary and sec-
ondary prevention therapy against atherothrombosis
and reduce cardiovascular mortality by30%, numer-
us clinical trials have failed to account for a clear
theroprotective effect (3). In contrast, a few experi-
ental studies have indicated that administration of
irect thrombin inhibitors in atherosclerotic mice
ubstantially inhibits plaque volume and results in
laque stability (7,8). Given the improved safety pro-M
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selective thrombin inhibition on plaque volume and
phenotype determination in patients.
Although the CAT method is meant to determine
the potential to generate thrombin in plasma in vitro,
the U-shaped association between ETP and CAD,
hich we demonstrate, may also be of physiological
elevance. We have previously reported that early
therosclerotic lesions show an increased thrombin
eneration potential in comparison to stable advanced
esions (5). Since the absence of angiographic CAD
oes not exclude early-stage morphological changes of
he arterial vessel wall (e.g., mild pathological intimal
hickening), one may assume that the increased
hrombin-forming capacity in the non-CAD group
ay be due to first signs of atherosclerotic alterations.
hrombin is a central enzyme in the coagulation-
nflammation axis and represents a potential therapeu-
ic target via which atherosclerosis might be modu-
ated. Moreover, thrombin is well known for its
ual-faceted character in both hemostasis and cell
ignaling (4). At very low concentrations, thrombin
an mediate numerous atheroprotective effects such as
ndothelial barrier protection, reduction in apoptosis
nd transendothelial migration of leukocytes, and
romote atheroprotective interleukin-10 synthesis
Table 2. Multivariate Models of Factors Associated With Odds o
Variable
Mild C
AS 1–
OR (95% CI)
Model 1: “Multinomial Logistic Regression:
Main Effects Model”
Reference (no CAC/AS 0) 1.00 (refe
Age 1.05 (1.01–1.09)
Gender (male  0) 2.61 (1.22–5.57)
Smoking (yes  1) 0.71 (0.32–1.53)
Diabetes mellitus (yes  1) 1.04 (0.30–3.61)
Positive family history (yes  1) 0.60 (0.31–1.16)
BMI 0.99 (0.91–1.08)
Total cholesterol 0.88 (0.66–1.15)
Systolic blood pressure 1.01 (0.99–1.04)
Diastolic blood pressure 1.00 (0.96–1.03)
TATc 1.56 (1.14–2.15)
Model 2: “Multinomial Logistic Regression:
Forward Stepwise Model”
Reference (no CAC/AS 0) 1.00 (refe
Age 1.05 (1.01–1.09)
Gender (male  0) 2.45 (1.25–4.81)
Positive family history (yes  1) 0.59 (0.31–1.11)
TATc 1.60 (1.18–2.16)
Statistical signiﬁcance at the p  0.05 level.
AS  Agatston score; BMI  body mass index; CAC  coronary artery calciﬁc39–41). Some of those actions are dependent on the soccupancy of endothelial protein C receptor by its
natural ligand protein C/activated protein C. Hence,
the net effect of specific long-term thrombin inhibi-
tion remains hard to predict.
Other ﬁndings. The role of CAC in inducing plaque
ulnerability remains controversial. Clinical evidence
hows that CAC is associated with coronary vasomo-
or dysfunction and reduced myocardial perfusion,
ven in the absence of luminal stenosis (42). Novel
oncepts of plaque vulnerability propose that athero-
clerotic plaque hypoxia may induce angiogenesis,
ntraplaque hemorrhage, and increased risk for rupture
43,44). Besides serving as a precise indicator of the
resence and severity of coronary plaque burden (45),
he Agatston score is considered a better predictor of
ardiovascular outcomes than the FRS (46). In the
urrent study, we present new evidence indicating
igher thrombin generation as an independent deter-
inant of CAC. Despite that the clinical significance
f these findings remains to be further investigated, a
ecent ex vivo human study reports that aortic valve
alcification can be induced through increased throm-
in generation (47).
Study limitations. First, we performed a single-center
tudy in which all patients were of Western European
escent. Second, the patient number was relatively
C
Moderate CAC
AS 100–400
S
p Value OR (95% CI) p Value OR (95%
ce) 1.00 (reference) 1.
0.021 1.12 (1.07–1.17) 0.005 1.15 (1.09–1
0.014 3.46 (1.50–8.01) 0.004 6.09 (2.17–1
0.377 0.51 (0.21–1.22) 0.132 0.34 (0.12–0
0.951 0.71 (0.19–2.61) 0.603 0.50 (0.12–2
0.127 0.42 (0.20–0.88) 0.021 0.41 (0.16–1
0.788 1.02 (0.93–1.12) 0.687 0.94 (0.83–1
0.346 0.96 (0.71–1.29) 0.769 0.84 (0.59–1
0.219 1.02 (0.99–1.04) 0.130 1.03 (1.00–1
0.911 1.00 (0.96–1.04) 0.973 0.99 (0.95–1
0.006 1.56 (1.13–2.15) 0.007 1.67 (1.21–2
ce) 1.00 (reference) 1.
0.010 1.12 (1.07–1.17) 0.005 1.16 (1.10–1
0.009 3.14 (1.49–6.61) 0.005 4.86 (1.98–1
0.104 0.40 (0.20–0.82) 0.012 0.40 (0.17–0
0.005 1.58 (1.16–2.15) 0.005 1.71 (1.26–2
; CI  conﬁdence interval; OR  odds ratio; TATc  thrombin-antithrombin comf CA
AC
100
evere CAC
AS >400
CI) p Value
ren 00 (reference)
.22) 0.005
7.07) 0.005
.95) 0.039
.17) 0.355
.01) 0.053
.06) 0.329
.21) 0.354
.06) 0.051
.04) 0.752
.31) 0.002
ren 00 (reference)
.21) 0.005
1.95) 0.005
.93) 0.034
.33) 0.005mall, which limits the options for analyzing the
Abbreviations as in Table
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1208relevance of TATc for predicting follow-up events.
Moreover, because the relatively healthy population,
we did not found a high rate of cardiovascular events,
Coronary Artery Disease (CAD)
n = 90
No
0%
123%
19 -127)
*
n = 67
Mild
< 50%
115%
(112 -119)
n =78
Moderate
50 -70%
121%
(116 -126)
n = 60
Severe
>70%
130%
(124 -135)
elationship Between ETP and CAD
nous thrombin potential (ETP) values (percent of normal pool
ed as mean (95% conﬁdence interval), stratiﬁed according to
osis. *Statistical signiﬁcance at the p  0.05 level when compared
ry artery disease group.
Logistic Regression Models for CAD Severity as the Dependent V
ble
Mild CAD
Stenosis <50%
OR (95% CI) p Value
Logistic Regression:
el”
0%]) 1.00 (reference)
1.08 (1.03–1.12) 0.005 1
2.50 (1.12–5.55) 0.025 3
0.62 (0.26–1.47) 0.276 0
s  1) 0.69 (0.20–2.36) 0.557 0
ry (yes  1) 0.60 (0.30–1.22) 0.160 0
0.98 (0.90–1.08) 0.704 1
0.77 (0.57–1.04) 0.093 0
ure 1.01 (0.98–1.03) 0.524 1
sure 1.00 (0.96–1.04) 0.939 1
1.37 (0.99–1.88) 0.056 1
Logistic Regression:
Model”
0%]) 1.00 (reference)
1.08 (1.03–1.12) 0.005 1
2.46 (1.20–5.08) 0.014 3
0.73 (0.32–1.65) 0.443 0
1.39 (1.02–1.89) 0.036 1
he p  0.05 level.
2.especially not in the short term, which is in line with
other CT studies. Third, while we screened for an-
giographic CAD, these findings may reflect other
existing atherosclerosis settings (carotid or peripheral
artery lesions), which we did not assess in this study.
Therefore, the association between thrombin forma-
tion and atherosclerosis in other vascular beds remain
open. Fourth, the purpose of this study was to inves-
tigate the association of thrombin formation and
CAD and was not meant to unravel this complex
causal relationship.
C O N C L U S I O N S
Thrombin formation is a useful tool in determining
the presence and severity of CAD, but more im-
portantly, may be also involved in the pathophysi-
ology of vascular calcification and atherosclerosis
progression.
Reprint requests and correspondence: Dr. Leonard Hofstra,
Cardiology Center Netherlands–Utrecht, Herculesplein 379,
3584 AA, Utrecht, the Netherlands. E-mail: l.hofstra@
ble
Moderate CAD
Stenosis 50–70%
Severe CAD
Stenosis >70%
(95% CI) p Value OR (95% CI) p Value
1.00 (reference) 1.00 (reference)
(1.04–1.13) 0.005 1.10 (1.05–1.15) 0.005
(1.37–6.69) 0.006 5.70 (2.33–13.94) 0.005
(0.23–1.28) 0.161 0.28 (0.12–0.67) 0.004
(0.23–2.89) 0.756 0.98 (0.23–4.28) 0.980
(0.31–1.25) 0.177 0.63 (0.30–1.34) 0.226
(0.95–1.14) 0.356 1.00 (0.90–1.10) 0.944
(0.61–1.11) 0.198 0.97 (0.72–1.32) 0.861
(0.99–1.04) 0.207 1.02 (0.99–1.04) 0.232
(0.97–1.04) 0.870 1.01 (0.97–1.05) 0.745
(1.16–2.14) 0.004 1.47 (1.07–2.02) 0.017
1.00 (reference) 1.00 (reference)
(1.05–1.13) 0.005 1.09 (1.05–1.14) 0.005
(1.52–6.41) 0.002 5.35 (2.38–12.03) 0.005
(0.29–1.46) 0.296 0.31 (0.14–0.69) 0.004
(1.18–2.14) 0.002 1.50 (1.11–2.04) 0.009M
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with the severe coronaTable 3. Multinomial aria
Varia OR
Model 1: “Multinomial
Main Effects Mod
Reference (no CAD [
Age .09
Gender (male  0) .02
Smoking (yes  1) .54
Diabetes mellitus (ye .82
Positive family histo .62
BMI .04
Total cholesterol .82
Systolic blood press .02
Diastolic blood pres .00
TATc .57
Model 2: “Multinomial
Forward Stepwise
Reference (no CAD [
Age .09
Gender (male  0) .12
Smoking (no  0) .65
TATc .59
Statistical signiﬁcance at tcardiologiecentra.nl, leonard.hofstra@gmail.com.
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